Fractyl Health, Inc., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on the stock and has a $8.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Fractyl Health, Inc.’s promising clinical data and strong financial position. The company has demonstrated clinically meaningful and statistically significant results with its Revita treatment, which shows potential to preserve weight loss after discontinuation of GLP-1 therapy. This potential is expected to be further validated with upcoming data readouts from the Pivotal Cohort, which are anticipated within the next year.
Additionally, Fractyl Health’s financial health is reinforced by its recent 3Q25 results, ending the quarter with $77.1 million in cash, providing a financial runway into early 2027. The company is also making strides in its manufacturing capabilities and has shown positive outcomes in its Germany Real-World Registry study, which further supports the long-term potential of its treatments. These factors collectively contribute to Pantginis’s positive outlook and Buy rating for Fractyl Health, Inc.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $5.00 price target.